ATAI Stock Analysis: Buy, Sell, or Hold?
ATAI - ATAI Life Sciences N.V. Common Shares
$7.17
-0.01 (-0.21%)
▼
5d:
-0.07%
30d:
+38.05%
90d:
+73.07%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 13, 2026
9d
Smart Money Accumulation
None View Scanner →
Strength: 5.9/10
Get Alerted When ATAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ATAI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ATAI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ATAI is currently trading at $7.17, which is considered extended relative to its 30-day fair value range of $5.12 to $7.15.
Technical Outlook: Technically, ATAI is in a strong uptrend. The price is currently testing key support at $7.13. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ATAI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.59 (+33.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ATAI is in a strong uptrend. The price is currently testing key support at $7.13. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ATAI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.59 (+33.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.12 -
$7.15
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 33.5% below Wall St target ($9.59)
Trading Range Analysis
30-Day Trading Range
$5.12 -
$7.15
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.13
Resistance Level
$7.21
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-15.76
Wall Street Target
$9.59
(+33.5%)
Revenue Growth (YoY)
-38.7%
Earnings Growth (YoY)
-96.8%
Share & Embed Analysis
Last updated: August 03, 2026 2:01 PM ET
Data refreshes hourly during market hours. Next update: 3:01 PM
Data refreshes hourly during market hours. Next update: 3:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Kevin James Craig
SELL
42579 shares
2026-04-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |
